Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease (vol 43, pg 871, 2020)

被引:1
|
作者
Wolters, Emma E. [1 ,2 ]
Ossenkoppele, Rik [2 ,3 ]
Verfaillie, Sander C. J. [1 ]
Coomans, Emma M. [1 ]
Timmers, Tessa [1 ,2 ]
Visser, Denise [1 ,2 ]
Tuncel, Hayel [1 ]
Golla, Sandeep S. V. [1 ]
Windhorst, Albert D. [1 ]
Boellaard, Ronald [1 ]
van der Flier, Wiesje M. [2 ,4 ]
Teunissen, Charlotte E. [5 ]
Scheltens, Philip [2 ]
van Berckel, Bart N. M. [1 ]
机构
[1] Vrije Univ Amsterdam, Dept Radiol & Nucl Med, Amsterdam Neurosci, Amsterdam UMC, Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Alzheimer Ctr Amsterdam, Dept Neurol, Amsterdam Neurosci,Amsterdam UMC, Amsterdam, Netherlands
[3] Lund Univ, Clin Memory Res Unit, Lund, Sweden
[4] Vrije Univ Amsterdam, Dept Epidemiol & Biostat, Amsterdam UMC, Amsterdam, Netherlands
[5] Vrije Univ Amsterdam, Neurochem Lab, Dept Clin Chem, Amsterdam UMC, Amsterdam, Netherlands
关键词
Atrophy; Cognition; CSF; PET; Tau; [!sup]18[!/sup]F]flortaucipir;
D O I
10.1007/s00259-020-04849-0
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: In vivo Alzheimer’s disease (AD) biomarkers for tau pathology are cerebrospinal fluid (CSF) phosphorylated tau (p-tau) and [18F]flortaucipir positron emission tomography (PET). Our aim was to assess associations between CSF p-tau with [18F]flortaucipir PET and the associations of both tau biomarkers with cognition and atrophy. Methods: We included 78 amyloid positive cognitively impaired patients (clinical diagnoses mild cognitive impairment (MCI, n = 8) and AD dementia (n = 45) and 25 cognitively normal subjects with subjective cognitive decline (SCD) (40% amyloid-positive)). Dynamic 130 min [18F]flortaucipir PET scans were acquired to generate binding potential (BPND) images using receptor parametric mapping and standardized uptake values ratios of 80–100 min (SUVr80-100min) post injection. We obtained regional BPND and SUVr from entorhinal, limbic, and neocortical regions-of-interest (ROIs), closely aligning to the neuropathological tau staging schemes. Cognition was assessed using MMSE and composite scores of four cognitive domains, and atrophy was measured using gray matter volume covering the major brain lobes. First, we used linear regressions to investigate associations between CSF p-tau (independent variable) and tau PET (dependent variable). Second, we used linear regressions to investigate associations between CSF p-tau, tau PET (separate independent variables, model 1), and cognition (dependent variable). We then assessed the independent effects of CSF p-tau and tau PET on cognition by simultaneously adding the other tau biomarker as a predictor (model 2). Finally, we performed the same procedure for model 1 and 2, but replaced cognition with atrophy. Models were adjusted for age, sex, time lag between assessments, education (cognition only), and total intracranial volume (atrophy only). Results: Higher [18F]flortaucipir BPND was associated with higher CSF p-tau (range of standardized betas (sβ) across ROIs, 0.43–0.46; all p < 0.01). [18F]flortaucipir BPND was more strongly associated with cognition and atrophy than CSF p-tau. When [18F]flortaucipir BPND and CSF p-tau were entered simultaneously, [18F]flortaucipir BPND (range sβ = − 0.20 to – 0.57, all p < 0.05) was strongly associated with multiple cognitive domains and atrophy regions. SUVr showed comparable results to BPND. Conclusion: Regional [18F]flortaucipir BPND correlated stronger with cognition and neurodegeneration than CSF p-tau, suggesting that tau PET more accurately reflects disease severity in AD. © 2020, The Author(s).
引用
收藏
页码:2934 / 2935
页数:2
相关论文
共 50 条
  • [21] Detection of tau in Gerstmann-Straussler-Scheinker disease (PRNP F198S) by [18F]Flortaucipir PET
    Risacher, Shannon L.
    Farlow, Martin R.
    Bateman, Daniel R.
    Epperson, Francine
    Tallman, Eileen F.
    Richardson, Rose
    Murrell, Jill R.
    Unverzagt, Frederick W.
    Apostolova, Liana G.
    Bonnin, Jose M.
    Ghetti, Bernardino
    Saykin, Andrew J.
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2018, 6 : 114
  • [22] Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers
    Ossenkoppele, Rik
    Reimand, Juhan
    Smith, Ruben
    Leuzy, Antoine
    Strandberg, Olof
    Palmqvist, Sebastian
    Stomrud, Erik
    Zetterberg, Henrik
    Scheltens, Philip
    Dage, Jeffrey L.
    Bouwman, Femke
    Blennow, Kaj
    Mattsson-Carlgren, Niklas
    Janelidze, Shorena
    Hansson, Oskar
    EMBO MOLECULAR MEDICINE, 2021, 13 (08)
  • [23] Visual assessment of [18F]flortaucipir PET across the Alzheimer's disease continuum and in dementia with Lewy Bodies
    Coomans, E.
    de Koning, L.
    Rikken, R.
    Verfaillie, S.
    Visser, D.
    den Braber, A.
    Lemstra, E.
    Scheltens, P.
    van der Flier, W.
    Ossenkoppele, R.
    van Berckel, B.
    van der Giessen, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S46 - S47
  • [24] Test-retest repeatability of [18F]Flortaucipir PET in Alzheimer's disease and cognitively normal individuals
    Timmers, Tessa
    Ossenkoppele, Rik
    Visser, Denise
    Tuncel, Hayel
    Wolters, Emma E.
    Verfaillie, Sander C. J.
    van der Flier, Wiesje M.
    Boellaard, Ronald
    Golla, Sandeep S., V
    van Berckel, Bart N. M.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2020, 40 (12): : 2464 - 2474
  • [25] Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (vol 77, pg 829, 2020)
    Fleisher, A. S.
    Pontecorvo, M. J.
    Devous, M. D.
    JAMA NEUROLOGY, 2023, 80 (08) : 873 - 873
  • [26] Biomarkers of Alzheimer's disease: Correlations between CSF p-TAU levels and cerebral glucose metabolism assessed with PET
    Borghetti, D.
    Giorgetti, A.
    Rossi, C.
    Kiferle, L.
    Frosini, D.
    Sassi, N.
    Petrozzi, L.
    Neglia, D.
    Murri, L.
    Ceravolo, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 : 196 - 196
  • [27] Detection of tau in Gerstmann-Sträussler-Scheinker disease (PRNP F198S) by [18F]Flortaucipir PET
    Shannon L. Risacher
    Martin R. Farlow
    Daniel R. Bateman
    Francine Epperson
    Eileen F. Tallman
    Rose Richardson
    Jill R. Murrell
    Frederick W. Unverzagt
    Liana G. Apostolova
    Jose M. Bonnin
    Bernardino Ghetti
    Andrew J. Saykin
    Acta Neuropathologica Communications, 6
  • [28] Neuropathologic correlates of tau by [18F]flortaucipir PET in Gerstmann-Straussler-Scheinker disease with the PRNP F198S mutation
    Risacher, Shannon
    Farlow, Martin
    Epperson, Francine
    Tallman, Eileen
    Richardson, Rose
    Murrell, Jill
    Bonnin, Jose
    Ghetti, Bernardino
    Saykin, Andrew
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2018, 77 (06): : 528 - 528
  • [29] Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease
    Edmond Teng
    Paul T. Manser
    Sandra Sanabria Bohorquez
    Kristin R. Wildsmith
    Karen Pickthorn
    Suzanne L. Baker
    Michael Ward
    Geoffrey A. Kerchner
    Robby M. Weimer
    Alzheimer's Research & Therapy, 13
  • [30] Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer's disease
    Teng, Edmond
    Manser, Paul T.
    Bohorquez, Sandra Sanabria
    Wildsmith, Kristin R.
    Pickthorn, Karen
    Baker, Suzanne L.
    Ward, Michael
    Kerchner, Geoffrey A.
    Weimer, Robby M.
    ALZHEIMERS RESEARCH & THERAPY, 2021, 13 (01)